RemeGen's Disitamab Vedotin Receives Fourth NMPA Approval for HER2-Low Breast Cancer in China
核心洞察
RemeGen's antibody-drug conjugate disitamab vedotin (RC48) received NMPA approval in China for treating adult patients with unresectable or metastatic HER2-low breast cancer (搜索) with liver metastases.
This marks the fourth approved indication for disitamab vedotin in China, expanding its therapeutic reach across gastric cancer (搜索), urothelial carcinoma (搜索), HER2-positive breast cancer (搜索), and now HER2-low breast cancer (搜索).
The approval targets patients who have received at least one prior systemic therapy in the metastatic setting or who relapsed during or within 12 months after adjuvant chemotherapy.
RemeGen Co., Ltd. has secured approval from China's National Medical Products Administration (NMPA) for a fourth indication of its antibody-drug conjugate disitamab vedotin (RC48), marking a significant expansion in the treatment landscape for breast cancer patients in China. The new approval authorizes the use of disitamab vedotin for adult patients with unresectable or metastatic HER2 (搜索)-low expressing breast cancer (IHC 1+ or IHC 2+/ISH−) with liver metastases.
Expanded Patient Population
The approval specifically covers patients who have received at least one prior systemic therapy in the metastatic setting, or those who experienced relapse during or within 12 months after adjuvant chemotherapy. This indication addresses a critical unmet medical need in the HER2-low breast cancer (搜索) population, a subset that has historically had limited targeted treatment options.
Growing Therapeutic Portfolio
This latest approval represents the fourth indication for disitamab vedotin in China, following previous approvals in gastric cancer (搜索), urothelial carcinoma (搜索), and HER2 (搜索)-positive advanced breast cancer with liver metastases. The expanding indication portfolio underscores the breadth of clinical evidence supporting what is recognized as China's first domestically developed ADC with breakthrough therapy designation from both Chinese and U.S. regulators.
Market Response and Investment Implications
Following the announcement, RemeGen's stock price increased by 30%, reflecting investor confidence in the expanded commercial potential of the therapy. According to market analysis, the approval sits within RemeGen's broader investment narrative of transforming a first-wave ADC and autoimmune portfolio into durable, diversified cash flows beyond a single-drug story.
The latest NMPA approval deepens the commercial reach of RC48 in China and may contribute incremental revenue on top of the company's projected 2025 profitability turnaround. However, market observers note that much of this regulatory momentum appears to have been quickly priced into the share price reaction.
Strategic Positioning
The approval reinforces disitamab vedotin's position as a versatile therapeutic platform capable of addressing multiple cancer types. The drug's success across gastric, urothelial, HER2 (搜索)-positive, and now HER2-low breast cancers demonstrates the potential for ADC technology to address diverse oncological indications through targeted delivery mechanisms.
Near-term catalysts for RemeGen continue to focus on execution of existing RC48 indications, the ramp-up of Telitacicept, and the translation of partnerships with AbbVie (搜索) and Vor Bio (搜索) into milestone and royalty streams. The company's investment case remains centered on its ability to leverage its lead assets into sustained commercial success while managing concentration risks associated with dependence on a limited number of key therapeutic programs.